Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 22:13:263-277.
doi: 10.2147/CEOR.S302097. eCollection 2021.

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

Maria Mareque  1 , Pau Montesinos  2 , Patricia Font  3 , José María Guinea  4 , Adolfo de la Fuente  5 , Javier Soto  6 , Itziar Oyagüez  1 , James Brockbank  7 , Tamara Iglesias  6 , Julia Llinares  6 , Jorge Sierra  8
Affiliations

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

Maria Mareque et al. Clinicoecon Outcomes Res. .

Erratum in

Abstract

Objective: To assess the incremental cost-utility ratio (ICUR) of gemtuzumab ozogamicin (GO) + standard of care (SOC) vs SOC alone for treatment of patients with de novo AML from a Spanish Health Service perspective.

Methods: A cohort state-transition model, with 12 health-states, was used to estimate the lifetime accumulated cost and benefits in terms of quality-adjusted-life-years (QALYs) in AML patients with favourable, intermediate, and unknown cytogenetic profiles. Patient profile was defined based on the ALFA-0701 trial. Therapeutic regimens were defined by 5 haematologists. SOC was assumed to be idarubicin and cytarabine, the combination most used in Spain. QALYs were estimated by applying utilities for the time spent by the cohort in each health-state and utility decrements associated with adverse events (AE). Total cost (€,2020) included drug-acquisition, hematologic stem-cell transplantation, disease management, AE management and end-of-life costs. Unit costs were derived from local databases. All parameters were validated by haematologist. Costs and outcomes were discounted (3%/year).

Results: Higher cost/patient (€177,618 vs €151,434) and greater QALYs (5,70 vs 4,62) were obtained with GO+SOC vs SOC. The ICUR was €24,203/QALY gained.

Conclusion: This simulation suggests that GO + SOC could be a cost-effective option for treatment of patients with de novo AML in first line.

Keywords: Spain; acute myeloid leukaemia; cost-effectiveness; gemtuzumab ozogamicin.

PubMed Disclaimer

Conflict of interest statement

Pau Montesinos, Patricia Font, Jorge Sierra, Adolfo de la Fuente and José María Guinea have received honoraria from Pfizer for advocacy tasks related to this project. Patricia Font is also the advisory board for BMS and Menarini. Jorge Sierra reports personal fees from Novartis, Astellas, Jazz Pharmaceuticals, and AbbVie, during the conduct of the study. María Mareque and Itziar Oyagüez are currently employed at PORIB, a consultant company specialized in economic evaluation of health interventions, which received financial support from Pfizer for the development of this study. Javier Soto, Tamara Iglesias and Julia Llinares are employees of Pfizer Spain. James Brockbank is employed of RTI Health Solutions. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Model structure diagram.
Figure 2
Figure 2
Results of one-way and probabilistic sensitivity analysis. (A) One-way sensitivity analysis. (B) Probabilistic sensitivity analysis.
See this image and copyright information in PMC

References

    1. Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721–749. doi:10.6004/jnccn.2019.0028 - DOI - PubMed
    1. Visser O, Trama A, Maynadié M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012;48(17):3257–3266. doi:10.1016/j.ejca.2012.05.024 - DOI - PubMed
    1. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099–2107. doi:10.1002/cncr.22233 - DOI - PubMed
    1. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. doi:10.1038/bcj.2016.50 - DOI - PMC - PubMed
    1. National Cancer Institute. Cancer stat facts: acute myeloid leukemia (AML); 2020. Available from: https://seer.cancer.gov/statfacts/html/amyl.html. Accessed April12, 2021.

LinkOut - more resources